Profile and Outcomes of Pediatric Hematology and Oncology Patients Diagnosed with COVID-19 in the Philippine General Hospital

Authors

  • Faustine Richelle C. Ong, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Philippine General Hospital, University of the Philippines Manila
  • Hazel Valerie T. Yu, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Philippine General Hospital, University of the Philippines Manila
  • Ana Patricia A. Alcasabas, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Philippine General Hospital, University of the Philippines Manila
  • Joliza Patricia D. Cañeba, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Philippine General Hospital, University of the Philippines Manila
  • Jochrys I. Estanislao, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Philippine General Hospital, University of the Philippines Manila
  • Pamela D. Fajardo, MD Division of Pediatric Hematology and Oncology, Department of Pediatrics, Philippine General Hospital, University of the Philippines Manila

DOI:

https://doi.org/10.47895/amp.v58i7.6865

Keywords:

COVID-19, pediatric hematology oncology, childhood cancer

Abstract

Introduction. The coronavirus pandemic has affected millions worldwide. Better understanding of COVID-19 in
pediatric hematology-oncology patients in a resource-limited setting is crucial to improve care as the pandemic
ensues.

Objectives. This study describes the clinical profile and outcomes of pediatric hematology oncology patients with COVID-19 seen at the Philippine General Hospital (PGH).

Methods. A retrospective, descriptive review of pediatric hematology oncology patients with COVID-19 seen
between March 2020 to March 2021 in PGH was done.

Results. Forty patients were identified. Seventeen percent had non-malignant hematologic conditions, 40% had
leukemias, and 42.5% had solid tumors. Fever and cough were the most common manifestations. Seventy-six
percent were on treatment, 9% were newly diagnosed, and 7% were in relapse or disease progression. Fifty-five
percent had mild COVID-19; 5% and 2.5% had severe and critical COVID-19, respectively. Thirty-seven percent
were asymptomatic. Cancer-related therapy was placed on hold for most patients. There were two mortalities, none was due to COVID-19.

Conclusion. Results suggest that patients with hematologic and oncologic conditions have a mild course, with
majority showing recovery from COVID-19. Delays in cancer-related therapy however, may contribute to disease
progression and mortality.

Downloads

Published

2024-04-30

How to Cite

1.
Profile and Outcomes of Pediatric Hematology and Oncology Patients Diagnosed with COVID-19 in the Philippine General Hospital. Acta Med Philipp [Internet]. 2024 Apr. 30 [cited 2025 Apr. 4];58(7). Available from: https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/6865